Calliditas Therapeutics Launches P-II Trial for Setanaxib in Alport Syndrome
Shots:
- Calliditas Therapeutics has initiated the P-II clinical study to evaluate setanaxib vs PBO in Alport syndrome, a rare genetic condition associated with kidney issues.
- The study involves approximately 20 patients diagnosed with Alport syndrome and notable proteinuria despite prior treatment with a renin-angiotensin system (RAS) blocker. The study duration is 24 wks., focusing on evaluating setanaxib's safety, tolerability, and its impact on UPCR and eGFR vs PBO
- Setanaxib is concurrently undergoing P-II evaluations for other indications, incl. squamous cell carcinoma of the head and neck, primary biliary cholangitis, and idiopathic pulmonary fibrosis.
Ref: PR Newswire | Image: Calliditas
Related News:- Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
